Document text
Principal Investigator: WILLIAM M GEISLER
Organization: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Fiscal Year: 2024
Award: $151,812
Funding agency: National Institute of Allergy and Infectious Diseases
This application is for a renewal of my K24 Midcareer Investigator Award in Patient-Oriented Research
(POR) on Chlamydia trachomatis (CT) Infections. I, Dr. William Geisler, am a federally-funded physician
scientist at the University of Alabama at Birmingham (UAB) with expertise in CT infections and significant
mentoring experience. During the initial K24 period, I obtained new funding (R01 renewal, a new R01, a new
R21, etc.), expanded my POR program in new directions, had 35 publications, became UAB Assistant Dean
for Physician Scientist Development, and mentored 16 early stage investigators who had many successes
(awards included a K08, KL2, TL1, an F30, an F31-D, etc.). The protected time afforded by this K24 renewal
would enable me to: 1) broaden my mentoring knowledge and develop new research skills, 2) continue
providing POR mentoring to early stage investigators, and 3) expand my research program in new directions.
Despite current CT prevention and control efforts, CT infection rates continue to rise and CT remains the most
prevalent bacterial STI worldwide, one with significant disparities in women and African Americans and
associated with reproductive morbidity. A CT vaccine is urgently needed. However, a better understanding of
immunogenetic determinants that impact CT infection risk and which CT antigens are most immunogenic and
induce protective immunity to CT is needed to advance vaccine development; My Current POR is focused on
this need (2R01AI093692 and 1R01AI148359). CT vaccine availability does not ensure it will be utilized.
Lessons learned from HPV vaccine implementation have taught us that psychosocial and behavioral factors
influence STI vaccine acceptability and studies on factors impacting CT vaccine acceptability are needed.
In this K24 renewal, I plan to broaden my mentoring knowledge through didactic and interactive
experiences, develop new research skills in entrepreneurship and research commercialization through didactic
and experiential training under mentorship, and continue mentoring early stage investigators in POR. Mentees
will be provided with educational and research experiences tailored to their career stage and interests.
Mentoring will be on my Current CT immunogenetics POR (noted above and discussed in detail in this
application) and on two new POR studies suported by this K24 renewal award that will expand my CT POR
program. New Study 1 aims to determine if HLA-DQB1*06 and CT-specific CD4+ IFN-g can be useful
biomarkers for predicting incident CT infection; I previously found that DQB1*06 was a risk marker and CD4+
IFN-g a protective marker for CT reinfection. Findings can be used to guide CT testing frequency in women
based on incident CT infection risk determined by the biomarkers. New Study 2 seeks to identify enabling and
limiting factors that affect acceptability of a CT vaccine through surveys and qualitative interviews to aid in
designing strategies to increase CT vaccine uptake. The long-term goal of my POR is to improve prevention
and control of CT infection. Thus, knowledge from Current POR and new studies addresses this goal.
Terms: <2019-nCoV vaccine><A vaginae><A. vaginae><Address><Adolescent><Adolescent Youth><Affect><African American group><African American individual><African American people><African American population><African Americans><Age><Alabama><Antibodies><Antigens><Area><Atopobium vaginae><Award><Behavioral><Biological Markers><Blood><Blood Reticuloendothelial System><Blood Serum><C trachomatis><C. trachomatis><COVID-19 vaccine><Chlamydia><Chlamydia trachomatis><Clinic><Clinical Investigator><DNA><Deoxyribonucleic Acid><Development><Doctor of Medicine><ELISA><Education><Educational aspects><Educational process of instructing><Enrollment><Entrepreneurial Skill><Entrepreneurship><Enzyme-Linked Immunosorbent Assay><Female><Frequencies><Funding><Genital Organs><Genitalia><Goals><Gynecology><HIV risk><HLA-DC><HLA-DC Antigens><HLA-DQ><HLA-DQ Antigens><HLA-DQB1><HLA-DQB1 antigen><HLA-DQbeta1><HLA-DS><HLA-DS Antigens><HLA-LB><HLA-LB Antigens><HLA-MB><HLA-MB Antigens><HPV Vaccine><Health><Human Papilloma Virus Vaccine><Human papillomavirus Vaccine><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><Immune Interferon><Immunity><Immunogenetics><Infection><Infection Control><Infection prevention><Interferon Gamma><Interferon Type II><International><Interview><Investigators><K24 Award><K24 Mechanism><K24 Program><Knowledge><Leadership><Linkage Disequilibrium><M.D.><M.P.H.><Master of Public Health><Mediating><Mentors><Mentorship><Micro RNA><MicroRNAs><Mid-Career Clinical Scientist Award (K24)><Midcareer Investigator Award in Patient-Oriented Research><Midcareer Investigator Award in Patient-Oriented Research (K24)><Miyagawanella><Mucosa><Mucosal Tissue><Mucous Membrane><NIH><National Institutes of Health><Patients><Physicians><Population><Position><Positioning Attribute><Prevent infection><Prevention><Public Health><Publications><R-Series Research Projects><R01 Mechanism><R01 Program><Reporting><Research><Research Activity><Research Grants><Research Personnel><Research Project Grants><Research Projects><Research Specimen><Researchers><Respondent><Rickettsia trachomae><Risk><Risk Marker><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Scientific Publication><Scientist><Secure><Serum><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Source><Specimen><Students><Survey Instrument><Surveys><Swab><T cell response><T-Cells><T-Lymphocyte><TL1><TNF Ligand-Related Molecule 1><TNF15><TNFSF15><TNFSF15 gene><Teaching><Testing><Time><Training><Translating><Tumor Necrosis Factor Ligand Superfamily Member 15><United States National Institutes of Health><Universities><VEGI><Vaccines><Variant><Variation><Vascular Endothelial Growth Inhibitor><Visit><Woman><accept vaccination><accept vaccine><access to vaccination><access to vaccines><ages><antigen based test><antigen test><bedsonia><bench bed side><bench bedside><bench to bed side><bench to bedside><bench to clinic><bench to clinical practice><bio-markers><biologic marker><biomarker><career><career development><chlamydia vaccine><clinical practice><commercialization><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><disparities affecting females><disparities affecting women><disparities among females><disparities among women><disparities facing women><disparities impacting women><disparities in females><disparities in women><early experience><enroll><enzyme linked immunoassay><experience><female disparities><immunogen><immunogenic><improved><infection rate><infection risk><insight><interest><juvenile><juvenile human><lFN-Gamma><male><miRNA><miRNAs><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><patient oriented research><patient oriented study><perinatal morbidity><predictive biomarkers><predictive marker><predictive molecular biomarker><programs><psychosocial><rate of infection><recruit><reproductive><reproductive morbidity><research study><response><risk predictor><risk predictors><sample collection><screening><screenings><skill acquisition><skill development><skills><specimen collection><success><thymus derived lymphocyte><vaccination acceptability><vaccination acceptance><vaccination access><vaccination availability><vaccination confidence><vaccination study><vaccination trial><vaccination uptake><vaccination willingness><vaccine acceptability><vaccine acceptance><vaccine access><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine availability><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine confidence><vaccine development><vaccine for novel coronavirus><vaccine study><vaccine trial><vaccine uptake><vaccine willingness><vaccines preventing COVID><vaccines to prevent COVID><women's disparities><young woman>